stockrow
Friday 6 November 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
44.89
6.02
+15.49%
Follow EWTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 92.15% | (38.03%) | (38.14%) | (34.19%) |
+8 more TTM periods Free account |
|
| 85.43% | (36.09%) | (36.18%) | (32.29%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
61.76% | (43.89%) | (35.58%) | (32.03%) | |
Free Cash Flow per Share |
(1.86) | (1.48) | (1.39) | (1.40) | |
Free Cash Flow |
(202.28) | (158.83) | (148.96) | (144.07) | |
Capital Expenditures |
(0.38) | (0.45) | (0.47) | (0.26) | |
| Other line items | |||||
Cash ROIC |
(5.99%) | (17.48%) | (15.01%) | (13.69%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
(0.20) | 0.80 | 0.84 | 0.86 | |
Depreciation/Fixed assets |
(0.58) | (0.44) | (0.60) | (0.69) | |
Capex/Depreciation |
0.10 | 0.15 | 0.11 | 0.05 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.85) | (1.47) | (1.39) | (1.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026